CorporatePresentation

October 2020

ForwardLookingStatement

Thisdocumentandanyattachmentsareintendedforinformationpurposesonlyandshouldnotbeconstruedasonofferorsolicitationforthesaleofsecurities.Statements inthispresentationincludeforward-lookingstatementswithinthemeaningofcertainsecuritieslaws.Theseforward-lookingstatementsinclude,amongothers,statementswithrespecttoourobjectives,goalsandstrategiestoachievethoseobjectivesandgoals,aswellasstatementswithrespecttoourbeliefs,plans,objectives,expectations,anticipations,estimatesandintentions.Thewords “expected to” “illustrate” “has thepotential to” “willbe”, “evaluating” “plans” “canbe” “planning” “to predict” “potential” “may” “should” andwords and expressions of similar import, areintendedtoidentifyforward-lookingstatements.Resultsinearlystageclinicaltrialsmaynotbeindicativeoffullresultsorresultsfromlaterstageorlargerscaleclinicaltrialsanddonotensureregulatoryapproval.Youshouldnotputunduerelianceonthesestatementorthescientificdatapresentedasanumberofimportantfactors,manyofwhicharebeyondourcontrol,couldcauseouractualresultstodiffermaterially fromthebeliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements.We do not undertake to update any forward-looking statements,whetherwritten ororal,thatmaybemadefromtimetotimebyusoronourbehalf;suchstatementsspeakonlyasofthedatemade. The forward-looking statements included herein are expressly qualified in their entirety by thiscautionarylanguage.

MissionStatement

TeloGenomicsprovidesactionableinformationthatisrelevanttomedicalprofessionals in themanagementof cancer and cognitivedisease. It is adiagnostic company that applies innovative and minimally-invasiveanalysisofgenomicinstability,basedonthe3Dorganizationoftelomeres,toimprovequalityoflifeandreducetreatmentcost.

ExecutiveSummary

4

Genomicinstabilityiscriticalintheevolutionofprecisionmedicineforcancerandcognitivedisease

TeloView®uses3Danalyticsoftelomerestoanalyzegenomicinstabilityasadiseasepredictor

Focusingontherapidlyemergingfieldofminimallyinvasive/liquidbiopsy

Evaluatedover3,000patients,130+peer-reviewedpapers&$25millionnon-dilutivefunding

Opportunitiesindiagnostic/prognosticproducts,pharma&academicpartnerships

CollaborationwiththeMayoClinicfocusingonunmetclinicalneedsinmultiplemyeloma

TeloView®–ExtensivelyDevelopedPlatform

5

14+ diseaseswithidentifiable3D

telomeresignatures

3,000+ patientsevaluated

25+ confirmatoryclinical

studies

130+ peer-reviewedpapers

18 patentsinCanada,USA

&Europe

$25M+ innon-dilutiveR&D

funding

Technology–TeloView®(3DTelomereAnalysis)

6

DNAispackagedintochromosomes.AtthetipsofeachchromosomeareprotectiveregionsofDNAcalledtelomeres

The3Dorganizationoftelomereswithinagivencellishighlypredictiveofgenomicinstability

AMeasureofGenomicInstability

Usingfluorescentmarkersandhighresolutionmicroscopes,thelocationofeachtelomerewithinacellnucleuscanbevisualizedanddigitallyanalyzed

TeloView®&GenomicInstability

7

TeloView®Single-cellAnalysis

-  Basedontheassessmentof6uniquetelomereparameters-  Cellsareanalyzedindividuallyusing3D-TelomereFISH*:

o  Representstheoverallgenomicinstabilityprofileofthepatiento  Canstratifypatientsbyprogression&theheterogeneityofcancers

-  Predictsresponsetotherapy&guidesprecisionmedicinetreatmentsolutions-  Requiresnomorethan100cellsanddoesnotrequireDNAamplification

First-in-class diagnostic/prognostic tool used to analyze genomic instability

Heterogeneityofcancer

-  Tumorsmayhavegroupsofcellsthatcontributedifferentlytotheaggressivenessofcancers-  Preciseprofilingofatumorshouldaccountforitsdistinctgroupsofcancercellsandrarecellsinguidingtreatment

*FISH FluorescentInSitu

Hybridization

Labelingoftelomereswithfluorescenttagscanbevisualizedandimagedin3Dusingamicroscope.Thefluorescentsignalscanthenbequantifiedtomeasurekeyfeaturesoftelomeres

TeloView®–WorkflowOutline

8

Personalized TeloView® Lab Report

TeloView®Analysis

ImageProcessing

3D Image Acquisition

3D – Telomere immuno-FISH

Sample Accession

4 5 6 1 3 2

Samples(fromblood,urine,etc.)areinspectedandassignedanID

Specificlabelingoftelomeresanddiseasespecificproteinswithfluorescenttags

Selectionofindividualtargetcells;adaptimageformatforTeloView®analysis

1.#ofTelomeres2.Telomerelengths3.Telomereaggregates4.a:cRatio5.Nuclearvolume6.Positioninnucleus

Personalizedresultsthatinformandguidetreatment

Acquiresconsecutiveimagesatconsecutivefocalplanesacrossthedepthofthesampletobuildone3Dimage

PrecisionMedicine

-  Thetailoringoftherapiesforgroupsofstratifiedpatientsbasedongenomic,life-style&environmentalfactors

-  Itleadstoimprovedclinicaloutcomes&qualityoflifeforpatientsandreducescostsinthelong-term

- 

GenomicInstability

-  Adefiningfeatureandcauseofcancer&otherdiseases-  Isanincreasedtendencyofgenomicmutationsduringcelldivision

Adetailedanalysisofgenomicinstabilitycanbeusedtostratifypatientsbyprogressionoftheirdisease&guidetreatment*

Industry–PrecisionMedicine&GenomicInstability

9

*MaiS.Thethree-dimensionalcancernucleus.GenesChromosomesCancer.2019;58:462–473.https://doi.org/10.1002/gcc.22720

MinimallyInvasive/LiquidBiopsyvTissueBiopsy

10

MinimallyInvasive/LiquidBiopsyo  Doesnotrequiresurgeryo  Usesliquids,hair,skin,etc.o  Capturescirculatingtumorcells(CTC’s)o  Faster,cheaper&painlesscomparedtosurgeryo  Repeatableformonitoringo  Providesgenomicanalysisofthenatureofcancers

Tissuebiopsyo  Requiresinvasivesurgeryo  Expensive($15000–$45,000)o  Painful&hardtorepeato  Riskofcomplicationso  Sideeffectso  Providesusefulgenomicinformation

LiquidBiopsyIndustry

11

•  Liquid-biopsyplatformsareattractingintenseinvestorinterest•  Pharmacompanies&VC’sinvestedover$1.2Bnin2018*

NextGenerationSequencing(NGS)o  Prevalentinliquidbiopsyo  Allowshighspeedandlowcostgenomicsequencingo  RequiresisolationofDNAcellsfollowedbyamplification(theproductionofmultiplecopies

oftargetedsequencesofDNA)o  Requireslargerstudiestocompensateforchallengingsignal-to-noiseratioo  Risksmissingthepotentialheterogeneityofthecancer

*https://www.prnewswire.com/news-releases/liquid-biopsy-poised-to-revolutionize-prognosis-and-early-detection-300757046.html

•  TeloView®doesnotuseNGSorDNAamplification,earlystudieshaveshownTeloView®maybeequivalentorbetterinprofilingprostatecancerbyitsaggressiveness*

*DrachenbergD,AweJ,PozzoA,SaranchukJandMaiS.AdvancingRiskAssessmentofIntermediateRiskProstateCancerPatients.Cancers2019,11,855;doi:10.3390/cancers11060855

TeloView®–MultipleMyeloma(MM)

12

•  Telo’sleadapplicationisadiagnostic/prognostictoolforunmetneedsacrossthespectrumofMM

•  MMisacancerofwhitebloodcells:o  Occursinplasmacells-atypeofwhitebloodcellthatgrowsinbonemarrowo  Symptomsincludebonepain/fractures,anemia,fatigue,recurrentinfections&kidney

problemso  Over140,000activecasesofMMintheUSin2020*o  Anincurablediseasethatcanbemoderatedthroughtreatment&hasa52%survival

rateover5years*

•  StandarddiagnosisforMMarebloodtestsandinvasivebonemarrowbiopsyandlimitedgenomictestingavailable

*https://seer.cancer.gov/statfacts/html/mulmy.html

MultipleMyeloma–DiseaseProgression

13

Initiation Progression

Clonalplasmacells

Post-germinalcentralBcell MGUS

SmolderingMultipleMyeloma

MultipleMyeloma

Plasmacellleukemia

Clonal,malignantplasmacells

•  Normalmatureplasmacells

•  Highlycomplicatedandaggressiveformofmyeloma

•  Symptomaticfullstageofthedisease

•  Abnormalmyelomacellsaccumulatedinthebonemarrow

•  AsymptomatichigherriskprecursorofMM

•  HigherlevelsofMproteins

•  Elevatedplasmainbonemarrow

•  AsymptomaticlowriskprecursorofMM

•  Mildlyelevatedantibodies(calledMproteins)

MultipleMyeloma–DiseaseProgression

14

TeloView®hasthepotentialtoguidediseasemanagementinmultipleareas

Initiation Progression

Post–germinalcentralBcell

MGUS

Clonalplasmacells

SmolderingMultipleMyeloma

MultipleMyeloma

Plasmacellleukemia

Clonal,malignantplasmacells

TELO-MM#1a TELO-MM#1b

MayoCollaboration#1a–MultipleMyeloma

15

AretrospectivestudydesignedtoshowsignificantdifferencesbetweenstableSMMpatientsvs.highriskSMMpatients

TransitionofSMMtoActiveMM

•  SMMisaprecursortoactiveMM:o  Standardofcarehasbeentomonitorbutnottreat,butischangingtoearlier

treatmentofhighriskpatientso  Currentdiagnosisisasimplebloodtestandinvasivebonemarrowbiopsyo  Thereareover250,000peoplewithSMMintheUS*o  13-14%SMMpatientstransitiontoactiveMMeachyear*

•  TeloView®isnon-invasive,itcanbeused2-3timesperyearinregularmonitoring•  Addressablemarketisover500,000testsperyear

TherearecurrentlynoteststhataccuratelypredictwhowilltransitionfromSMMtoactiveMM

*RavindranA,BartleyAC,HoltonSJ.Prevalence,incidenceandsurvivalofsmolderingmultiplemyelomaintheUnitedStates.BloodCancerJournal(2016)6,e486;publishedonline21October2016

MayoCollaboration#1b–MultipleMyeloma

16

MMistreatedwithcombinationtherapy,thereareover40differentcombinationsavailable,gettingtherightinitialtherapyiscritical:

o  Itcandelaysymptomsandorgandamage,improvingoutcomesandreducingcostso  Patientsbuildupresistancetotherapyandcanchangecombinationsmultipletimeso  Typesoftreatmentincludes;chemotherapy,immunotherapy,proteasomeinhibitors,stemcell

therapyandradiationo  Annualcostoftherapyis$125-250ko  Thereareover32,000newcasesofMMayearintheUS*o  Addressablemarketforguidinginitialtherapyisover32,000testsperyear,andover100000

testsperyearwhenchangingtherapies

AretrospectivestudydesignedtoshowsignificantdifferencesbetweenMMpatientswhofailedinitialtherapyfromthosewhoremainedinremission

InitialResponsetoTherapyinMM

*https://seer.cancer.gov/statfacts/html/mulmy.html

MultipleMyeloma–RepresentativePublications

17

Summary#22016studyconductedon10patientsex-vivo

•  Tested3MMdrugsunderdevelopmentforefficacy•  SuccessfullyshowedthatTeloView®couldpredictpatientresponsetoeachdrug

-  Thefollowingkeysummariesarefrompeerreviewedpublications(2013-2019)-  Included158patientswithMM,SMMorMGUS&providedthecatalystfortheMayoCollaboration

Summary#12013studyincluded86patients

•  Establishedproofofconcept• Canbeconductedwithliquidbiopsy•  Stratifiespatientsbydistinct3Dtelomereprofilesforstageofthedisease

Summary#32019studyincluded62patients

• UsedTeloView®tostratifypatientsbydistinct3Dtelomereprofile•  Successfullystratified&groupedpatientsbetweenMGUS&activeMM

0 1,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000

List

Pric

e ($

USD

) GenomicTesting=PremiumPricing

18

Commercialization

19

There are several potential paths to revenues: •  Licenseorsaledirectlytopharmaceuticalcompaniesforresearchorasa

companiondiagnostic•  Licenseorsalewithdiagnosticlaboratorycompaniesorestablisheddiagnostic

companies•  DirectsalesthroughasinglespecializedCLIAlaboratoryasaLabDevelopedTest

(LDT)•  Directsaleswithaninvitrodiagnostictest(IVT)underFDAapprovalasanew

product

TeloView®informsonarangeofcancersandneurologicaldiseases

20

MultipleMyelomaHodgkin’sLymphomaMyelodysplasticSyndrome/AcuteMyeloidLeukemiaChronicMyeloidLeukemia

ProstateCancerAlzheimer’sDiseaseLungCancer(NSCLC)

BreastCancerMelanomaCutaneousLymphomaPancreaticCancerThyroidCancerHeadandNeckCancerOralCancerEsophagealCancer

TeloView®

GastrointestinalCancerRhabdomyosarcomaEpendymomaCholangiocarcinomaGlioblastomaOligodendrogliomaNeuroblastoma

TELOLeadership

21

SabineMai,PhD,DirectorandChair,Clinical&ScientificAdvisoryBoardProfessor,UniversityofManitoba,TIER-ICanadaResearchChairfromTheCanadianInstituteofHealthResearch.Aworldleaderin3Dmicroscopy,telomeresbiology,genomicinstabilityandcancer.

SherifLouis,PhD,PMP,ChiefExecutiveOfficerAnexperiencedbusinessleaderandaccomplishedscientistwithstrongtrackrecordinthebiotechnologyindustryfocusedontechnologydevelopmentandcommercialization.

GuidoBaechler,Chairman25yearsofexperienceworkingwithemergingtechnologiesinlifesciences/medicaldiagnostics.ServedasPresident&ChiefExecutiveOfficerofSingulex.PriortoSingulex,heldexecutiveleadershippositionsatbothRocheDiagnosticsandRocheMolecularDiagnostics.

Clinical&ScientificAdvisoryBoard

22

Sabine Mai, PhD – Chair, Clinical & Scientific Advisory Board

Kenneth C. Anderson, MD – Harvard & Dana-Farber Cancer Institute (USA)

Laurence Klotz, MD – Sunnybrook Hospital (Canada) Hans Knecht, MD – McGill & The Jewish General Hospital (Canada)

Darrel Drachenberg, MD – CancerCare Manitoba (Canada)

Pubco&Capitalization

23

SharesIssued:

52-WeekRange:

RecentPrice:(10/15/20)

MarketCap:

PrivatePlacement:(11/25/2019)

ProjectBurnRate:

42.0m

$0.30-$0.10

$0.21

$8.8m

$1.74m

<$100k/mo.

InvestmentSummary

24

•  TeloView®isafirst-in-classprognostic/diagnostictoolusedtoanalyzegenomicinstabilityasapredictorofdiseaseandguidetreatment

•  Uniquespaceintherapidlyemergingfieldofminimallyinvasive/liquidbiopsy•  CollaborationwiththeMayoClinic,focusingonunmetclinicalneedsinmultiple

myeloma(MM),usingTeloView®topredict:o  TransitionfromsmolderingMMtoactiveMMo  EfficacyofinitialtherapyinMMo  Theaddressablemarketfortheseindicationsisover$1.0billion

•  Over130+peer-reviewedpapersevaluatingover3,000patientsand14+diseases•  Opportunitiesindiagnostic/prognosticproducts,pharmaceuticalpartnershipsand

academiccollaborations

ContactInformation

25

MaRSDiscoveryDistrict101CollegeSt.,Suite200Toronto,Ontario,Canada

E:info@telodx.comT:416.673.8487